<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109798</url>
  </required_header>
  <id_info>
    <org_study_id>BCM IRB#H-16155</org_study_id>
    <secondary_id>CDR0000427313</secondary_id>
    <nct_id>NCT00109798</nct_id>
  </id_info>
  <brief_title>Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma</brief_title>
  <official_title>Phase II Trial of Salvage Chemotherapy With Temozolomide in Combination With Topotecan for Primary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide and topotecan, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving temozolomide together with topotecan&#xD;
      works in treating patients with primary CNS lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the complete radiologic response rate in patients with primary CNS lymphoma&#xD;
           treated with salvage chemotherapy comprising temozolomide and topotecan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the median and failure-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall response rate in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive oral temozolomide once daily on days 1-5 and topotecan IV over 30 minutes&#xD;
      once daily on days 2-6. Treatment repeats every 28 days for 6-8 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 1 year, and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sub-Investigator reloacted to another institution&#xD;
  </why_stopped>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete radiologic response (CR)</measure>
    <time_frame>July 2006</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>July 2006</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>July 2006</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>July 2006</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (CR and partial response)</measure>
    <time_frame>July 2006</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide, Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Patient will take drug on day 1-5 of 28 day schedule</description>
    <arm_group_label>Temozolomide, Topotecan</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Patient will have IV on days 2-6 on a 28-day schedule</description>
    <arm_group_label>Temozolomide, Topotecan</arm_group_label>
    <other_name>Topotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary CNS lymphoma at initial diagnosis&#xD;
&#xD;
          -  Measurable tumor by radiography&#xD;
&#xD;
          -  Failed* OR is not a candidate for first-line high-dose systemic methotrexate-based&#xD;
             chemotherapy with or without radiotherapy NOTE: *Failure is defined as relapse,&#xD;
             progression, or failure to achieve a complete response&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and SGPT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known allergy to temozolomide or topotecan&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or stage I or II cancer in complete remission&#xD;
&#xD;
          -  No other major medical illness or psychiatric impairment that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  At least 2 weeks since prior methotrexate&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior non-nitrosourea cytotoxic drugs (except methotrexate)&#xD;
&#xD;
          -  At least 4 weeks since prior systemic investigational agents&#xD;
&#xD;
          -  At least 2 weeks since prior non-cytotoxic antitumor drugs&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
&#xD;
        EXCLUSION CRITERA&#xD;
&#xD;
          1. Patients who are pregnant or breastfeeding, or females of childbearing potential not&#xD;
             using adequate contraception.&#xD;
&#xD;
          2. Known allergy to temozolomide or topotecan.&#xD;
&#xD;
          3. Severe vomiting or other inability to administer medications orally.&#xD;
&#xD;
          4. Major medical illnesses or psychiatric impairment that in the investigator's opinion&#xD;
             will prevent administration or completion of the protocol therapy and/or will&#xD;
             interfere with follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Z. New, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>primary central nervous system Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

